Skip to main content

Table 1 Patient Characteristics

From: Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study

Characteristic Patients
All LC CRC Other
(n = 30) (n = 15) (n = 10) (n = 5)
Sex, n (%)
 M 24 (80.0) 12 (80.0) 8 (80.0) 4 (80.0)
 F 6 (20.0) 3 (20.0) 2 (20.0) 1 (20.0)
Age (years), median (range) 66.5 (39–79) 68.0 (43–79) 62.5 (43–75) 56.0 (39–75)
ECOG PS, n (%)
 0–1 24 (80.0) 12 (80.0) 8 (80.0) 4 (80.0)
 2 4 (13.3) 3 (20.0) 0 (0.0) 1 (20.0)
 3 2 (6.7) 0 (0.0) 2 (20.0) 0 (0.0)
Stage, n (%)
 IIB-IIIA 3 (10.0) 2 (13.3) 0 (0.0) 1 (20.0)
 IIIB-ΙΙΙC 3 (10.0) 2 (13.3) 0 (0.0) 1 (20.0)
 IV 22 (73.3) 10 (66.7) 9 (90.0) 3 (60.0)
Postoperative recurrence, n (%) 2 (6.7) 1 (6.7) 1 (10.0) 0 (0.0)
Line of cancer chemotherapy at the commencement of concurrent chemotherapy, n (%)
 Adjuvant 1 (3.3) 0 (0.0) 0 (0.0) 1 (20.0)
 First 21 (70.0) 9 (60.0) 8 (80.0) 4 (80.0)
 Second 3 (10.0) 3 (20.0) 0 (0.0) 0 (0.0)
 Third or higher 5 (16.7) 3 (20.0) 2 (20.0) 0 (0.0)
Diabetes mellitus, n (%)
 Y 7 (20.7) 3 (20.0) 2 (20.0) 2 (40.0)
 N 23 (79.3) 12 (80.0) 8 (80.0) 3 (60.0)
MTB diagnosis, n (%)
 Before anti-CCT 20 (66.7) 8 (53.3) 8 (80.0) 4 (80.0)
 During anti-CCT 10 (33.3) 7 (46.7) 2 (20.0) 1 (20.0)
  1. Abbreviations CCT cancer chemotherapy, CRC colorectal cancer, ECOG Eastern Cooperative Oncology Group, F female, LC lung cancer, M male, MTB Mycobacterium tuberculosis, N no, PS performance status, Y yes